|
|
Time |
Source |
|
Announcement
|
|
| 16 Sep 2019 |
8:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Indices for the eleventh year running |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche receives FDA clearance for cobas pro integrated solutions designed to help labs deliver faster results to patients |
| 13 Sep 2019 |
6:03 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer |
| 12 Sep 2019 |
6:03 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy |
| 10 Sep 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS |
| 06 Sep 2019 |
6:03 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer |
| 04 Sep 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS |
| 03 Sep 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. |
| 02 Sep 2019 |
6:10 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86% |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche presents positive phase III study results for one-dose Xofluza in children with flu |
| 29 Aug 2019 |
6:03 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer |
| 16 Aug 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours |
| 05 Aug 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche’s Tecentriq plus platinum-based chemotherapy reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer |
| 31 Jul 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. |
| 26 Jul 2019 |
12:18 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer |
| |
12:15 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer |
| 25 Jul 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche reports very strong performance in the first half of 2019 – Outlook raised |
| 22 Jul 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche expands the Global Access Program beyond HIV to also include diagnostic tests for Tuberculosis, Hepatitis, and Human Papillomavirus |
| 09 Jul 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress |
| 28 Jun 2019 |
11:45 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
CHMP recommends EU approval of Roche’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer |
| 18 Jun 2019 |
7:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Japan becomes the first country to approve Roche’s personalised medicine Rozlytrek |
| 11 Jun 2019 |
6:03 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Changes in Roche's Board of Directors and Corporate Executive Committee |
| 10 Jun 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche and Spark Therapeutics, Inc. receive Request for Additional Information from FTC under Hart-Scott-Rodino Act and announce extension of tender offer for shares of Spark Therapeutics, Inc. |
| 04 Jun 2019 |
4:09 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine |
| 03 Jun 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting |
| 02 Jun 2019 |
12:30 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer shows positive data in those with liver metastases |
| 31 May 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche and GE Healthcare launch NAVIFY Tumor Board with medical imaging capabilities to enable more personalised treatment decisions in cancer care |
| 16 May 2019 |
6:03 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents |
| 14 May 2019 |
6:03 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
New Roche test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting antimicrobial resistance within the world's leading cause of infectious disease deaths |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. |
| 10 May 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche to present new data highlighting comprehensive approach to cancer care at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting |
| 08 May 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche to present new OCREVUS (ocrelizumab) data analyses showing significant reduction of disability progression in relapsing and primary progressive multiple sclerosis at the AAN Annual Meeting |
| 07 May 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche presents data from the risdiplam pivotal FIREFISH and SUNFISH studies in spinal muscular atrophy at the 2019 AAN Annual Meeting |
| 06 May 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
FDA approves Roche's Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment |
| 29 Apr 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
New Roche data at the 2019 AAN Annual Meeting showcase breadth and promise of neuroscience portfolio |
| 26 Apr 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. |
| 23 Apr 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy |
| 17 Apr 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche reports a strong start in 2019 and raises the outlook for the full-year |
| 03 Apr 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. |
| 01 Apr 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche's ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial |
| 19 Mar 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer |
| 15 Mar 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
European Commission approves Roche's MabThera (rituximab) for a rare autoimmune disease |
| 14 Mar 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
European Commission approves Roche's Hemlibra for people with severe haemophilia A without factor VIII inhibitors |
| 11 Mar 2019 |
6:03 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
FDA grants Roche's Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer |
| 08 Mar 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
European Commission approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer |
| 07 Mar 2019 |
4:35 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash |
| |
1:38 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions |
| 05 Mar 2019 |
1:23 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche Annual General Meeting 2019 |
| 28 Feb 2019 |
4:35 pm |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers |
| 25 Feb 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche enters into definitive merger agreement to acquire Spark Therapeutics |
| 19 Feb 2019 |
6:03 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
FDA grants Priority Review to Roche's personalised medicine entrectinib |
| |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
FDA grants Priority Review to Roche's polatuzumab vedotin in previously treated aggressive lymphoma |
| 06 Feb 2019 |
6:00 am |
GNW
|
|
|
F. Hoffmann-La Roche Ltd (0QQ6) |
Roche joins the World Federation of Hemophilia Humanitarian Aid Program |